Back to Results
First PageMeta Content
Dipeptidyl peptidase-4 inhibitors / Thiazolidinediones / Amides / Eli Lilly and Company / Pioglitazone / Exenatide / Anti-diabetic medication / Metformin / Rosiglitazone / Chemistry / Organic chemistry / Anti-diabetic drugs


Submission to the PBAC Post Market Review of Products Used in the Management of Diabetes: Drug Utilisation and Listing Review Boehringer Ingelheim welcomes the opportunity to comment on the Post-Market Review of Products
Add to Reading List

Document Date: 2014-10-01 22:38:57

Open Document

File Size: 118,86 KB

Share Result on Facebook

City

Trial / /

Company

Medline / /

Country

Germany / France / Australia / /

Facility

Royal Australian College of General Practitioners / Cochrane Library / /

Holiday

Commonwealth Day / /

IndustryTerm

diabetes products / diabetes management / listed products / conservative search strategy / line diabetes product / basic literature search / combination products / prescribed diabetes products / treatment algorithm / /

MedicalCondition

diabetes complications / only third line diabetes / congestive heart failure / Disease / inappropriately prescribed diabetes / reimbursed diabetes / bladder cancer / Diabetes / prescribed diabetes / myocardial infarction / chronic kidney disease / heart failure / chronic disease / angina / line diabetes / blindness / /

MedicalTreatment

amputations / /

Movie

The National Health / /

Organization

National Health and Medical Research Council / Food and Drug Administration / European Medicines Agency / Therapeutic Goods Association / European Association for the Study of Diabetes / Royal Australian College of General Practitioners / American Diabetes Association / International Diabetes Federation / /

Position

investigator / representative / /

Product

pioglitazone / Avandamet / glucagon / glimepiride / Avandia / Rosiglitazone / /

PublishedMedium

the Diabetes Review / /

Technology

treatment algorithm / /

SocialTag